Have a feature idea you'd love to see implemented?
Let us know!
BCAB BioAtla Inc
Price (delayed)
$1.39
Market cap
$67.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.7
Enterprise value
$11.94M
BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms.
Highlights
BCAB's debt has shrunk by 56% YoY and by 25% QoQ
The company's EPS rose by 36% YoY and by 22% QoQ
The equity has dropped by 76% year-on-year and by 27% since the previous quarter
BioAtla's quick ratio has decreased by 27% YoY and by 18% QoQ
Key stats
What are the main financial stats of BCAB
Market
Valuations
Earnings
Shares outstanding
48.35M
Market cap
$67.2M
Enterprise value
$11.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.93
Price to sales (P/S)
6.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.09
Revenue
$11M
EBIT
-$81.82M
EBITDA
-$80.75M
Free cash flow
-$85.08M
Per share
Balance sheet
Liquidity
EPS
-$1.7
Free cash flow per share
-$1.76
Book value per share
$0.48
Revenue per share
$0.23
TBVPS
$1.29
Total assets
$62.24M
Total liabilities
$39.27M
Debt
$1.25M
Equity
$22.97M
Working capital
$41.11M
Debt to equity
0.05
Current ratio
3.11
Quick ratio
2.9
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
-734.1%
Gross margin
100%
Net margin
-743.8%
Operating margin
-784%
Return on assets
-96.3%
Return on equity
-187.3%
Return on invested capital
N/A
Return on capital employed
-191.3%
Return on sales
-743.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCAB stock price
How has the BioAtla stock price performed over time
Intraday
-6.08%
1 week
-18.71%
1 month
-28.72%
1 year
-13.13%
YTD
-43.5%
QTD
-21.02%
Financial performance
How have BioAtla's revenue and profit performed over time
Revenue
$11M
Gross profit
$11M
Operating income
-$86.24M
Net income
-$81.82M
Gross margin
100%
Net margin
-743.8%
BCAB's operating income is up by 34% YoY and by 22% from the previous quarter
BioAtla's net income has increased by 34% YoY and by 22% QoQ
Growth
What is BioAtla's growth rate over time
Valuation
What is BioAtla stock price valuation
P/E
N/A
P/B
2.93
P/S
6.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.09
The company's EPS rose by 36% YoY and by 22% QoQ
The equity has dropped by 76% year-on-year and by 27% since the previous quarter
BCAB's P/B is 9% above its last 4 quarters average of 2.7 but 2.3% below its 5-year quarterly average of 3.0
Efficiency
How efficient is BioAtla business performance
The company's return on equity has shrunk by 110% YoY and by 10% QoQ
BioAtla's ROA has decreased by 48% YoY
Dividends
What is BCAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCAB.
Financial health
How did BioAtla financials performed over time
The company's total assets is 58% higher than its total liabilities
The company's total assets has shrunk by 59% YoY and by 9% QoQ
The total liabilities has declined by 31% year-on-year but it has increased by 5% since the previous quarter
BCAB's debt is 95% lower than its equity
The equity has dropped by 76% year-on-year and by 27% since the previous quarter
BioAtla's debt to equity has surged by 67% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.